Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
Peng Guo, Jing Huang, Bing Zhu, et al.
Science Advances (2023) Vol. 9, Iss. 18
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 103
Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer
Pengfei Huang, Xinyue Zhou, Minying Zheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 25
Rational Identification of Novel Antibody‐Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors
Yu Guo, Zheyuan Shen, Wenbin Zhao, et al.
Advanced Science (2024) Vol. 11, Iss. 13
Open Access | Times Cited: 8
Age-dependent loss of HAPLN1 erodes vascular integrity via indirect upregulation of endothelial ICAM1 in melanoma
Gloria E Marino-Bravante, Alexis E. Carey, Laura Hüser, et al.
Nature Aging (2024) Vol. 4, Iss. 3, pp. 350-363
Closed Access | Times Cited: 8
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Youngbo Choi, Y. Choi, Surin Hong
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 221-221
Open Access | Times Cited: 6
Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
Mariana Ribeiro Monteiro, Natália Abou Hala Nunes, Aumilto Junior, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 51-70
Open Access | Times Cited: 5
Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody–drug conjugate development
Peng Zhang, Changjuan Tao, Hanfei Xie, et al.
Gastric Cancer (2025)
Open Access
Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer
Shili Yao, Lu Sun, Ye Lu, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Mechanisms underlying neutrophils adhesion to triple-negative breast cancer cells via CD11b-ICAM1 in promoting breast cancer progression
Chenghui Yang, Lili Li, Zhiqiang Ye, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation
Wen‐Jing Qian, Jinshan Yan, Xiaoyu Gang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189187-189187
Closed Access | Times Cited: 4
Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting
Danqing Zhu, Wonjoon Kim, Hyunjin Lee, et al.
Advanced Materials (2025)
Closed Access
Targeted Nanoprobes Enabled Precision Theranostics in Triple‐Negative Breast Cancer
Ke Ma, Meng Yin, Kezheng Chen, et al.
The Chemical Record (2025)
Closed Access
Challenges and opportunities in single-domain antibody-based tumor immunotherapy
Xiaozhi Xi, Guo Shu-hua, Yuchao Gu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189284-189284
Closed Access
Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment
Idil Buyukgolcigezli, Ateş Kutay Tenekeci, Ibrahim Halil Sahin
Cancers (2025) Vol. 17, Iss. 6, pp. 958-958
Open Access
Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates
Hanfei Xie, Lu Sun, Shili Yao, et al.
Gynecologic Oncology (2025) Vol. 196, pp. 16-27
Closed Access
Recent Progress of Multifunctional Molecular Probes for Triple-Negative Breast Cancer Theranostics
Deyi Zhao, Zhe Li, Ding‐Kun Ji, et al.
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 803-803
Open Access | Times Cited: 3
Intercellular Adhesion Molecule 1 (ICAM-1): An Inflammatory Regulator with Potential Implications in Ferroptosis and Parkinson’s Disease
Matthew Miller, Harold E. Landis, Robert E. Miller, et al.
Cells (2024) Vol. 13, Iss. 18, pp. 1554-1554
Open Access | Times Cited: 2
Nitric oxide inhibits FTO demethylase activity to regulate N6-methyladenosine mRNA methylation
Hannah Petraitis Kuschman, Marianne B. Palczewski, Brian M. Hoffman, et al.
Redox Biology (2023) Vol. 67, pp. 102928-102928
Open Access | Times Cited: 6
Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma
Peng Zhang, Changjuan Tao, Ye Lu, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 1
TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review
Ying Pan, Qiancheng Zhao, Haitao He, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody‐Drug Conjugates in Preclinical Models
L.B. Ma, Yan‐zhi Xu, Yuxuan Yang, et al.
Advanced Therapeutics (2024) Vol. 7, Iss. 8
Open Access
A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2
Weixu Feng, Zhuo Chen, Lianpeng Wu, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113362-113362
Open Access
AuNP@DNA nanoflares: Preparation and application in bioanalysis and biomedicine
Le Yang, Huige Wei, Zhihe Qing, et al.
Chinese Chemical Letters (2024), pp. 110524-110524
Closed Access
Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives
Sharada Sawant, Gaurav Gopal Naik, Alakh N. Sahu, et al.
Medical Oncology (2024) Vol. 41, Iss. 12
Closed Access
Small molecule-drug conjugates: Mechanistic insights and strategic design for enhanced cancer therapy
Jiawei Zhu, Yucheng Xiong, Xiaoxue Bai, et al.
Chinese Chemical Letters (2024), pp. 110799-110799
Closed Access
Page 1 - Next Page

Scroll to top